WJPPS Citation

Login

Search

News & Updation

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.
  •  
  • Updated Version
  • WJPPS introducing updated version of OSTS (online submission and tracking system), which have dedicated control panel for both author and reviewer. Using this control panel author can submit manuscript
  • Call for Paper
    • WJPPS  Invited to submit your valuable manuscripts for Coming Issue.
  • ICV
  • WJPPS Rank with Index Copernicus Value 84.65 due to high reputation at International Level

  • Scope Indexed
  • WJPPS is indexed in Scope Database based on the recommendation of the Content Selection Committee (CSC).

  • WJPPS: New Impact Factor 2026
  • WJPPS Impact Factor has been Increased to 8.485 for Year 2026.

  • WJPPS: MAY ISSUE PUBLISHED
  • MAY 2026 Issue has been successfully launched on 1 MAY 2026.

Abstract

HIGH-POTENCY ACTIVE PHARMACEUTICAL INGREDIENTS: MANUFACTURING STRATEGIES, CONTAINMENT TECHNOLOGIES, AND OCCUPATIONAL SAFETY CONSIDERATIONS

Vishal Shah*

ABSTRACT

The increasing demand for targeted therapies in oncology and rare diseases has driven the rapid expansion of high-potency active pharmaceutical ingredient (HPAPI) manufacturing. These compounds, characterized by occupational exposure limits (OELs) below 10 μg/m³ and often in the nanogram range, require specialized engineering controls, toxicological assessment, and occupational safety programs. This review examines current HPAPI manufacturing strategies, focusing on containment technologies, health-based exposure limits, and regulatory requirements. The derivation of health-based limits such as Permitted Daily Exposure (PDE) and Occupational Exposure Limits (OELs) forms the foundation of risk assessment, supported by Occupational Exposure Banding (OEB) for early-stage compounds. Facility architecture relies on the "Onion Model" of containment, integrating negative-pressure HVAC systems with 100% single-pass air, HEPA filtration, and Bag-In/Bag-Out (BIBO) housings. Primary containment includes rigid barrier isolators, split butterfly valves (SBVs), and rapid transfer ports (RTPs) for OEB 4 and 5 substances. Critical unit operations—micronization, weighing, dispensing—are performed within fully enclosed systems to prevent airborne release. Cleaning validation has shifted from traditional limits to health-based exposure limits (HBELs), utilizing Maximum Allowable Carryover (MACO) calculations based on PDE values. Occupational safety programs incorporate powered air-purifying respirators (PAPRs), double-gloving, medical surveillance, and real-time industrial hygiene monitoring. Emerging digital tools, including computational fluid dynamics (CFD) and digital twins, enable predictive containment design and continuous monitoring. Successful HPAPI manufacturing integrates robust toxicology, advanced engineering controls, and comprehensive occupational health programs to protect workers and ensure product quality.

Keywords: Hpapi, Containment, Occupational Exposure Limit (Oel), Cleaning Validation, High-Potency Manufacturing.


[Download Article]     [Download Certifiate]

Call for Paper

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Online Submission

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More

Email & SMS Alert

World Journal of Pharmacy and Pharmaceutical Sciences (WJPPS)
Read More